低剂量皮下地西他滨治疗骨髓纤维化的多中心2期临床试验
这项前瞻性多中心2期试验纳入21例骨髓纤维化患者(18例慢性期、2例加速期、1例急变期),给予皮下地西他滨0.3 mg/kg每日一次、连续10天方案。总缓解率为33%(95%CI 15-57),主要表现为血细胞减少改善;中位缓解持续时间7个月(范围3-44)。所有患者均出现至少1种3/4级血细胞减少,非血液学毒性以乏力、厌食和低钙血症最常见。
要点
- 21例骨髓纤维化患者接受皮下地西他滨0.3 mg/kg每日一次、连续10天方案,总缓解率33%(95%CI 15-57)。
- 缓解主要表现为血细胞减少改善,中位缓解持续时间7个月(范围3-44)。
- 所有患者均出现至少1种3/4级血细胞减少,非血液学毒性以乏力、厌食、低钙血症最常见。
核心结论
- 鉴于伴有严重血细胞减少的骨髓纤维化缺乏有效疗法,本研究支持进一步研究低甲基化药物单药或联合治疗。
研究设计与样本
- 前瞻性、多中心、2期临床试验,纳入21例骨髓纤维化患者(18例慢性期、2例加速期、1例急变期)。
- 治疗方案为皮下地西他滨0.3 mg/kg每日一次、连续10天。
- 试验注册号为NCT00095784。
主要发现
- 总缓解率为33%(95%CI 15-57),主要表现为血细胞减少改善。
- 中位缓解持续时间为7个月(范围3-44)。
- 国际预后评分系统高风险评分、基线胎儿血红蛋白水平高以及循环CD34+细胞计数持续下降与地西他滨缓解相关。
- 所有患者均出现至少1种3/4级血细胞减少;非血液学毒性较少见,最常见为乏力、厌食和低钙血症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) in the chronic phase is a challenging disease to treat, and conventional treatment options are geared toward symptom palliation. In this prospective, multicenter, phase 2 trial, 21 patients with MF (18 chronic phase, 2 accelerated phase, and 1 blast phase) were treated with a 10-day schedule of subcutaneous decitabine at 0.3 mg/kg per day. The overall response rate was 33% (95% confidence interval, 15-57), primarily manifested as an improvement in cytopenias. The median duration of response was 7 months (range, 3-44). A high International Prognostic Scoring System risk score, high baseline fetal hemoglobin level, and sustained decrease in circulating CD34+ cell counts were associated with response to decitabine. All patients experienced at least 1 grade 3/4 cytopenia. Nonhematologic toxicities were less frequent, with fatigue, anorexia, and hypocalcemia being the most common. Given the lack of effective therapies in MF with severe cytopenias, this study supports further investigation into the use of hypomethylating agents as single agents or in combination therapies. This trial was registered at www.ClinicalTrials.gov as #NCT00095784.
引用
- Lin C, Patel AA, Huo D, et al. A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024. PMID: 39250708. doi:10.1182/bloodadvances.2024013215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。